Domov › Ateroskleroza › Texas

Klinične študije za Ateroskleroza v Texas

11 študij za Ateroskleroza išče udeležence na lokacijah v Texas.

Mesta v Texas

Uradno besedilo študije (angleško)

A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event

Horizon Clinical Research Group, Cypress
Cardiovascular Specialists of Willowbrook, Houston
Texas Cardiology Associates of Houston, Kingwood
in še 2

Vključevanje udeležencevFaza 2

Starost 18 in več · Vsi spoli · Posodobljeno 30. sep. 2026 · NCT07783802

A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events

Southwest Family Medicine Associates, Dallas
East Texas Cardiology PA, Houston
Cardiovascular Specialists of Willowbrook, Houston
in še 1

Vključevanje udeležencevFaza 2

Starost 18 in več · Vsi spoli · Posodobljeno 29. sep. 2026 · NCT07448038

Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)

PharmaTex Research, Amarillo
St. David's Heart & Vascular PLLC dba Austin Heart, Austin
Velocity Clinical Research, Austin, Austin
in še 18

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 24. sep. 2026 · NCT07157774

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

PharmaTex Research, LLC, Amarillo
Austin Heart, Austin
Velocity Clinical Research - Austin, Austin
in še 22

Vključevanje udeležencevFaza 3

Starost 45–99 · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT07037433

A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis

PharmaTex Research, LLC, Amarillo
Pulse Care Heart and Vascular, Carrollton
DM Clinical Research - Dallas, Tomball

Vključevanje udeležencevFaza 2

Starost 18–80 · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT07521007

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

Cussimanio Research Group LLC, Austin
Research Management, Inc., Austin
MW Clinical Research Center, Beaumont
in še 22

Vključevanje udeležencevFaza 2/3

Starost 18 in več · Vsi spoli · Posodobljeno 21. sep. 2026 · NCT05485961

A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event

Research Site, Amarillo
Research Site, Beaumont
Research Site, Brownsville
in še 33

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 24. avg. 2026 · NCT07000357

Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD

PharmaTex Research LLC, Amarillo
Kelsey Seybold Research Foundation, Houston
Northwest Houston Clinical Research PLLC, Tomball

Vključevanje udeležencevFaza 3

Starost 18–80 · Vsi spoli · Posodobljeno 7. avg. 2026 · NCT06813911

Pelacarsen Roll-over Extension Program

Plano Primary Care Clinic, Allen
Pharma Tex Research, Amarillo
SW Family Medicine Associates, Dallas
in še 8

Vključevanje udeležencevFaza 3

Starost 18–100 · Vsi spoli · Posodobljeno 29. jul. 2026 · NCT06875973

Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes

VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX, Dallas
Michael E. DeBakey VA Medical Center, Houston, TX, Houston

Vključevanje udeležencevFaza 4

Starost 18 in več · Vsi spoli · Posodobljeno 17. dec. 2025 · NCT02915198

Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)

UT Health Houston, Houston

Vključevanje udeležencevFaza 2

Starost 40 in več · Vsi spoli · Posodobljeno 17. dec. 2025 · NCT05488431

Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.